首页 | 本学科首页   官方微博 | 高级检索  
检索        

舒降之与赖诺普利对冠心病相关因子HCY的影响
引用本文:刘喜,赵兴胜,刘艳玲.舒降之与赖诺普利对冠心病相关因子HCY的影响[J].内蒙古医学杂志,2011,43(3):280-282.
作者姓名:刘喜  赵兴胜  刘艳玲
作者单位:内蒙古自治区人民医院心内科,内蒙古,呼和浩特,010017
摘    要:目的:观察冠心病(coronary heart disease,CHD)患者血浆同型半胱氨酸(homocysteine,HCY)水平在舒降之与赖诺普利作用下的变化情况。方法:①选择我科门诊及住院稳定型心绞痛患者385例,抽取空腹静脉血检测HCY。②血浆HCY〉15μmol/L的140例患者随机分为4组:A组常规组:阿司匹林+硝酸酯类药;B组舒降之组:舒降之(10 mg,1次/d)+常规治疗。C组赖诺普利组:赖诺普利(5 mg,1次/d)+常规治疗。D组联合组:舒降之(10 mg,1次/d)+赖诺普利(5 mg,1次/d)+常规治疗。治疗4周后再次检测HCY。结果:①385例老年稳定型心绞痛患者中血浆HCY〉15μmol/L者165例,约占42.86%。②A组治疗前后差异无统计学意义(P〉0.05)。B、C、D组治疗后血浆HCY水平显著降低,差异有统计学意义(P〈0.01)。③B组与C组比较差异无统计学意义(P=0.994)。④D组与B、C组比较差异有统计学意义(D组与B组比较,P=0.043;D组与C组比较,P=0.042)。结论:①冠心病患者血浆HCY水平升高;②舒降之与赖诺普利均可降低老年稳定型心绞痛患者血浆HCY水平,且二者具有协同作用。

关 键 词:同型半胱氨酸  冠心病  舒降之  赖诺普利

The Effect of Zocor and Lisinopril on CHD-Related Factor HCY
LIU Xi,ZHAO Xing-sheng,LIU Yan-ling.The Effect of Zocor and Lisinopril on CHD-Related Factor HCY[J].Inner Mongolia Medical Journal,2011,43(3):280-282.
Authors:LIU Xi  ZHAO Xing-sheng  LIU Yan-ling
Institution:(Department of Cardiology,Imner Mongdia Autonomous Region People's Hospital,Huhhot 010017 China)
Abstract:Objective:To investigate the level of plasma homocysteine(HCY) in patients with CHD before and after treated with zocor and lisinopril.Methods:①With draw the anticoagulative blood from the empty stomach of outpatients and inpatients with stable angina,then measured the level of HCY.There were total 385 cases enrolled in the study.② 140 cases with plasma HCY 15 μmol/l were randomly divided into four groups:Group A,routine group :aspirin + nitrates;Group B,zocor group:zocor(10 mg,1 time/day) + routine therapy;Group C,lisinopril group:lisinopril(5 mg,1 time/day) + routine therapy;and Group D,alliance group: zocor(10 mg,1 time/ day) + lisinopril(5 mg,1 time/day) + routine therapy.The level of HCY was measured again 4 weeks later.Results: ①Among 385 cases,165 patients whose plasma HCY 15μmol/L,accounted for 42.86%.②The level of plasma HCY in Group A had no statistically significant difference before and after treatment(P0.05),but it was significantly decreased in all of Group B,C and D,and the differences had extremely statistical significance(P0.01).③There was no significant difference between Group B and C(P=0.994);④Compared Group D with B and C,The difference were significant(between group D and B,P=0.043;between group D and C,P=0.042).Conclusions: ①The level of plasma HCY increased in patients with CHD;②Both zocor and lisinopril could reduce the level of plasma HCY in old patients with stable angina,and furthermore,there was synergistic action between them.
Keywords:Homocysteine  Coronary heart disease  Zocor  Lisinopril
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号